These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 10418915)

  • 21. Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model.
    Marr N; Oliver DC; Laurent V; Poolman J; Denoël P; Fernandez RC
    Vaccine; 2008 Aug; 26(34):4306-11. PubMed ID: 18582518
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of chosen parameters of immuno response in mice immunized with whole-cell or acellular pertussis vaccines and challenged with B. pertussis strains harbouring different ptxS1/prn allele genes combinations].
    Gzyl A; Augustynowicz E; Zawadka M; Rabczenko D; Slusarczyk J
    Med Dosw Mikrobiol; 2007; 59(2):137-47. PubMed ID: 17929411
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bordetella pertussis, Finland and France.
    Caro V; Elomaa A; Brun D; Mertsola J; He Q; Guiso N
    Emerg Infect Dis; 2006 Jun; 12(6):987-9. PubMed ID: 16707058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.
    Bouchez V; Brun D; Cantinelli T; Dore G; Njamkepo E; Guiso N
    Vaccine; 2009 Oct; 27(43):6034-41. PubMed ID: 19666155
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bordetella pertussis Strain Lacking Pertactin and Pertussis Toxin.
    Williams MM; Sen K; Weigand MR; Skoff TH; Cunningham VA; Halse TA; Tondella ML;
    Emerg Infect Dis; 2016 Feb; 22(2):319-322. PubMed ID: 26812174
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan.
    Kodama A; Kamachi K; Horiuchi Y; Konda T; Arakawa Y
    J Clin Microbiol; 2004 Dec; 42(12):5453-7. PubMed ID: 15583264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Construction of Bordetella pertussis strains with enhanced production of genetically-inactivated Pertussis Toxin and Pertactin by unmarked allelic exchange.
    Buasri W; Impoolsup A; Boonchird C; Luengchaichawange A; Prompiboon P; Petre J; Panbangred W
    BMC Microbiol; 2012 Apr; 12():61. PubMed ID: 22524455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years.
    Weber C; Boursaux-Eude C; Coralie G; Caro V; Guiso N
    J Clin Microbiol; 2001 Dec; 39(12):4396-403. PubMed ID: 11724851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013.
    Quinlan T; Musser KA; Currenti SA; Zansky SM; Halse TA
    Mol Cell Probes; 2014 Aug; 28(4):138-40. PubMed ID: 24365130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution.
    Mooi FR; van Oirschot H; Heuvelman K; van der Heide HG; Gaastra W; Willems RJ
    Infect Immun; 1998 Feb; 66(2):670-5. PubMed ID: 9453625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.
    Hegerle N; Guiso N
    Expert Rev Vaccines; 2014 Sep; 13(9):1135-46. PubMed ID: 24953157
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impaired long-term maintenance and function of Bordetella pertussis specific B cell memory.
    Stenger RM; Smits M; Kuipers B; van Gaans-van den Brink J; Poelen M; Boog CJ; van Els CA
    Vaccine; 2010 Sep; 28(40):6637-46. PubMed ID: 20637762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pertussis Vaccine Candidate Based on Outer Membrane Vesicles Derived From Biofilm Culture.
    Carriquiriborde F; Martin Aispuro P; Ambrosis N; Zurita E; Bottero D; Gaillard ME; Castuma C; Rudi E; Lodeiro A; Hozbor DF
    Front Immunol; 2021; 12():730434. PubMed ID: 34603306
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Construction and characterization of single-chain variable fragment antibodies directed against the Bordetella pertussis surface adhesins filamentous hemagglutinin and pertactin.
    Hussein AH; Davis EM; Halperin SA; Lee SF
    Infect Immun; 2007 Nov; 75(11):5476-82. PubMed ID: 17724067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pertactin deficient Bordetella pertussis present a better fitness in mice immunized with an acellular pertussis vaccine.
    Hegerle N; Dore G; Guiso N
    Vaccine; 2014 Nov; 32(49):6597-600. PubMed ID: 25312274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003.
    Byrne S; Slack AT
    BMC Infect Dis; 2006 Mar; 6():53. PubMed ID: 16542440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.
    Hegerle N; Paris AS; Brun D; Dore G; Njamkepo E; Guillot S; Guiso N
    Clin Microbiol Infect; 2012 Sep; 18(9):E340-6. PubMed ID: 22717007
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A consideration of control requirements for acellular pertussis vaccines.
    Corbel MJ; Xing DK
    Dev Biol Stand; 1997; 89():343-7. PubMed ID: 9272369
    [No Abstract]   [Full Text] [Related]  

  • 39. Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.
    Hijnen M; He Q; Schepp R; Van Gageldonk P; Mertsola J; Mooi FR; Berbers GA
    Scand J Infect Dis; 2008; 40(2):94-104. PubMed ID: 17926203
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of FHA and Prn on Bordetella pertussis colonization of mice is dependent on vaccine type and anatomical site.
    Zeddeman A; van Schuppen E; Kok KE; van Gent M; Heuvelman KJ; Bart MJ; van der Heide HGJ; Gillard J; Simonetti E; Eleveld MJ; van Opzeeland FJH; van Selm S; de Groot R; de Jonge MI; Mooi FR; Diavatopoulos DA
    PLoS One; 2020; 15(8):e0237394. PubMed ID: 32822419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.